#USA #San Diego #Discovery Life #Tumoroid Cell #OncoPro Medium

Discovery Life Sciences Launches Tumoroids for Oncology Research

HUNTSVILLE, AL – Discovery Life Sciences, recognized globally for its pioneering contributions to biospecimen solutions and specialized lab services, is set to launch its innovative Tumoroid Cell Lines at the upcoming Precision Med Tri-Con 2025. This significant event is scheduled to take place from March 11 to 13 in San Diego, California.

The Tumoroid Cell Lines, cultivated from patient-derived cancer cells, are engineered within Thermo Fisher Scientific's Gibco™ OncoPro™ Tumoroid Culture Medium. This cutting-edge development is expected to significantly propel oncology research forward, enabling scientists to assess and identify effective therapies more efficiently. McLean Collins, President of Biospecimens Products & Services at Discovery, highlighted the importance of this launch: “Our tumoroid cell lines are a transformative tool that can help eliminate major barriers to oncology research, giving scientists a powerful, predictive tool to identify life-changing therapies faster.”

Enhancing Oncology Research with Tumoroids

The Tumoroid Cell Lines are designed as three-dimensional (3D) multicellular structures that mimic the biological complexity of cancer. Unlike traditional two-dimensional (2D) cancer models, these tumoroids provide greater biological relevance, offering vital environmental dynamics that are essential for drug and diagnostic development. This advancement signifies a major milestone in the effort to produce therapies that are more effective and targeted, enhancing the potential for breakthroughs in patient care.

Key Events at Precision Med Tri-Con 2025

During the Precision Med Tri-Con, Discovery Life Sciences aims to engage with the scientific community through various presentations and discussions:

• - Luncheon Presentation: Dr. Shawn Fahl, Vice President of Lab Operations, Cell Services & RD, will discuss From Biorepository to Breakthroughs: Accelerating Development with Spatial and Transcriptomic Analyses. This is part of the Spatial Biology and Single-Cell Multiomics program on March 11.
• - Keynote Panel: On March 12, Dr. Fahl will participate in a keynote panel titled Tech Trends in Precision Medicine, sharing insights into emergent innovations in the field.
• - Poster Presentation: The team will also present findings on Cell-Free DNA and Beyond: A Comprehensive Evaluation of Liquid Biopsy Workflows Across a Global Clinical Biorepository.

Dr. Fahl expressed enthusiasm about Discovery's presence at the conference, stating, “We will be showcasing several exciting studies, highlighting our dedication to advancing precision medicine by integrating advanced technologies and high-quality biospecimens into our workflows.” The event promises a platform for collaborative exploration of cutting-edge science and technology in oncology research.

Commitment to Innovation and Patient Outcomes

Discovery Life Sciences remains dedicated to advancing research and improving patient outcomes through its strategic investments in advanced technology. This includes innovations in AI-powered pathology and retrospective clinical biomarker testing workflows which provide actionable insights from biospecimens.

As a leading force in the realm of biospecimen solutions, Discovery Life Sciences continues to position itself at the forefront of life science research, striving to be the most trusted partner in therapeutic and diagnostic development. For more details about Discovery Life Sciences and its offerings, visit www.dls.com.

Note: Gibco™ and OncoPro™ are trademarks of Thermo Fisher Scientific and its subsidiaries, with all products designated for Research Use Only, prohibiting diagnostic applications.